Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.00.

A number of research firms have recently weighed in on CMPX. Citigroup initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Citizens Jmp set a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. William Blair reissued an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Tuesday, January 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Thursday, March 5th.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vivo Capital LLC increased its stake in shares of Compass Therapeutics by 70.0% in the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after purchasing an additional 2,487,443 shares in the last quarter. Suvretta Capital Management LLC boosted its position in Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after purchasing an additional 6,951,666 shares in the last quarter. Monashee Investment Management LLC boosted its position in Compass Therapeutics by 657.6% during the third quarter. Monashee Investment Management LLC now owns 1,250,000 shares of the company’s stock worth $4,375,000 after purchasing an additional 1,085,000 shares in the last quarter. CM Management LLC acquired a new stake in Compass Therapeutics in the third quarter valued at approximately $525,000. Finally, Tema Etfs LLC acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $538,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $5.45 on Wednesday. The stock has a market cap of $981.49 million, a price-to-earnings ratio of -12.67 and a beta of 1.48. The firm’s 50-day moving average is $5.93 and its two-hundred day moving average is $4.93. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. On average, equities analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.